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Mutations in PRKNǯǤ ?
ubiquitin ligase, functioning in mitophagy. Mitochondrial abnormalities are present in PRKN mutant 
models. Patient derived neurons are a promising model in which to study pathogenic mechanisms and 
therapeutic targets. Here we generate induced neuronal progenitor cells from PRKN mutant patient 
ƤǤ
ơǤ	 ? ?
PRKN mutant patients were transformed into induced neuronal progenitor cells and subsequently 
ơǤǡ
ƪǡ
ƤǤPRKNƤ
ơǤ
were able to observe changing mitochondrial phenotypes as neurons undergo a metabolic switch 
ơǤǦơ
mitophagy is unimpaired by PRKNƤǤ
dependent, mitophagy is severely impaired in the PRKN mutant patient neurons. These changes 
correlate with changes in mitochondrial function and morphology; resulting in lower neuron yield 
and altered neuronal morphology. Induced neuronal progenitor cell conversion can produce a high 
yield of dopaminergic neurons. The mitochondrial phenotype, including mitophagy status, is highly 
dependent on the metabolic status of the cell. Only when neurons are oxidative phosphorylation 
ƤǤ
ƤơPRKN mutations, in particular in relation to mitophagy dependent disease 
phenotypes and provide avenues for alternative therapeutic approaches.
Parkinson’s disease (PD) is the second most common neurodegenerative disease, with approximately 10 mil-
lion people afected worldwide. Only symptomatic treatment options are available. Mutations in PRKN are the 
most common cause of early onset PD (EOPD). Parkin is an E3 ubiquitin ligase and functions in the mitophagy 
 pathway1. Mitochondrial dysfunction is well established in both familial and sporadic forms of PD (recently 
 reviewed2). Mitochondrial abnormalities are present in both PRKN null  Drosophila3 and  mice4. We and others 
have shown mitochondrial abnormalities in peripheral cells from patients with PRKN  mutations5–8; these include 
cellular ATP defects, mitochondrial membrane potential deiciencies, complex I defect and altered mitochondrial 
morphology. Recent work suggests mitophagy is defective across many PD  types9. Several reports have found 
alterations in the same mitochondrial parameters in iPSC derived PRKN deicient  neurons10–17. hese studies 
provide insight into a mitochondrial phenotype in PRKN deicient neurons; several have identiied mitochondrial 
functional and morphological abnormalities as well as increased cell death occurring in PRKN mutant neurons. 
Dopaminergic (DA) neurons are particularly vulnerable to mitochondrial abnormalities due to their high basal 
oxidative load, tonic activity and highly complex arborisation of the dendritic  network18. he studies so far have 
utilised the iPSC reprogramming route and subsequent diferentiation into DA neurons, which can generate a 
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relatively poor yield of DA neurons as relected by % TH positive cells reported in these  studies13,14,19. herefore, 
there remain some unanswered questions about the speciic role and importance of mitochondrial abnormalities 
in a PRKN deicient background in DA neurons. In particular, a study has suggested the diferentiation method 
from iPSC’s is important to be able to identify mitochondrial dysfunction in DA  neurons10.
he role of parkin in the mitophagy pathway is extremely well documented mainly in tumour cell lines over 
expressing parkin with mitophagy induction due to treatment with uncoupling agents such as CCCP. Limited 
studies have investigated the role of parkin dependent mitophagy in cells expressing endogenous parkin and 
fewer still without the induction of mitophagy via uncoupling. Recent indings from several in vivo models have 
called into question the relative importance of parkin dependent mitophagy in adult DA neurons with studies 
in PINK1 deicient mice and PRKN and PINK1 deicient Drosophila showing no diference in mitophagy rates 
in DA  neurons20,21. However an age dependent increase in mitophagy in DA neurons which is absent in PRKN 
and PINK1 deicient Drosophila has also been  identiied22. herefore more studies are needed to elucidate the 
importance of mitophagy in PRKN deicient EOPD.
Our study uses a direct conversion route from patient ibroblasts to induced neuronal progenitor cells (iNPC’s) 
and subsequently to DA neurons with a high yield. Direct reprogramming methods result in cells that both retain 
the genetic background and the age phenotype of the donor  ibroblasts23. With a high yield of DA neurons we 
are able to study the mitochondrial and mitophagy phenotypes throughout diferentiation in this speciic cell 
population. his study aims to provide evidence for mitochondrial abnormalities in PRKN mutant patient derived 
DA neurons, using an alternative method to previous studies, in addition to investigate if the reprogramming 
and diferentiation methodology generates diferent mitochondrial phenotypes. We show that mitophagy defects 
are dependent on the metabolic status of the cell; with high mitophagy rates in PRKN deicient neurons early 
in diferentiation when the cells are mainly glycolytic and mitophagy rates which are extremely low in PRKN 
deicient neurons reliant upon oxidative phosphorylation. We also show treatment with known potent intracel-
lular redox-modulating agents improves the neuronal phenotype of the neurons without restoring mitochondrial 
function or morphology.
Results
Ǥ Unlike iPSC reprogramming of ibroblasts, 
the direct conversion method irst developed by Meyer et al. produces iNPC’s which are tripotent and able to dif-
ferentiate into neurons, astrocytes and  oligodendrocytes24. he iNPC’s produced using this methodology can be 
diferentiated into speciic neuronal populations with a high purity yield, as demonstrated for motor  neurons25. 
We successfully converted ibroblasts from 4 control and 4 PRKN mutant patients producing iNPC’s which dis-
played a clear change in cell morphology, proliferation rate and stained positive for the NPC markers, Pax6 and 
nestin as found previously for all iNPC’s reprogrammed using this  methodology24–27 (data not shown).
In order to be able to investigate biochemical parameters in DA neurons without other neuronal types or 
non-neuronal cells contaminating the culture; a high yield of DA neurons is required. We optimised the DA 
diferentiation protocol based upon Swistowski and co-workers28. Diferentiation is in three stages, irst iNPC’s 
are treated with DAPT, a Notch inhibitor that enhances neuronal diferentiation; in stage 2 the cells are driven 
towards a rostral midbrain neuronal lineage and inally in stage 3 DA neuron diferentiation is complete. As 
diferentiation proceeds the cellular morphology alters; at day 15 of diferentiation cells have become elongated 
and begun to form connections as compared to iNPC morphology and by day 27 the cells have formed longer, 
larger connections (Fig. 1A shows brightield images of cells at two stages of diferentiation). he morphology 
is distinct from the parental iNPC morphology. However, we note, the processes are shortened and thicker than 
those usually seen in neurons diferentiated from iPSC’s or primary embryonic cultures. herefore, we sought to 
characterise the expression of several pan-neuronal markers and DA speciic markers throughout diferentiation. 
We assessed expression of pan neuronal markers βIII tubulin, MAP2 and NeuN at various stages of diferen-
tiation (day 12, day 17 and day 27). he amount of cells staining positive for each of these markers increases 
throughout diferentiation, resulting at day 27 in 94.5% of cells staining for βIII tubulin, 87.9% for MAP2 and 
76.5% for NeuN (quantiication throughout diferentiation is shown in Fig. 1B–D with representative images 
at day 27 shown for each marker in a control and a PRKN mutant line). Next, we investigated the expression of 
two DA markers, tyrosine hydroxylase (TH) and the dopamine transporter (DAT). Again, expression increases 
throughout diferentiation; with undetectable levels of TH and DAT expression at day 17 of diferentiation. At 
day 27 of diferentiation however 89.9% of cells stain positive for TH and 82.4% for DAT (Fig. 1E,F quantiica-
tion throughout diferentiation and representative images at day 27 of diferentiation). In addition, we quantiied 
mRNA transcript level for TH at day 27 as compared to iNPC’s and found a 4.2 fold increase in DA neurons 
compared to iNPC’s (Fig. 1G). Neurosensor 521 dye labels both noradrenaline and dopamine in live cells, and 
we found that at end stage of diferentiation 87.8% of cells stained positive with Neurosensor 521 (Fig. 1H). We 
next sought to measure the dopamine content and stimulated release of dopamine from our neuronal cultures. 
We found that the neurons had measurable intracellular dopamine and the neurons could be stimulated to 
release dopamine using potassium chloride in a magnesium containing bufer. PRKN mutant neurons contain 
less intracellular dopamine than controls (mean ± SD, controls 111.8 ± 2.6, parkin mutants 88.4 ± 3.4 nmol/l 
dopamine; p < 0.001; Fig. 1I). Upon stimulation with potassium chloride the amount of dopamine in the media 
increases in controls by 51% and only by 15% in PRKN mutant patients (Fig. 1I). he neurons do not release 
dopamine when stimulated with potassium chloride without magnesium present. Finally, we also assessed the 
cellular membrane potential to assess neuronal properties of our cells in culture. We ind positive staining for 
membrane potential and luctuations as expected in active neuronal cultures (Fig. 1J); however, the PRKN mutant 
neurons are less responsive to stimuli.
 ?
Vol.:(0123456789)
SCIENTIFIC REPORTS |        (2020) 10:15485  | ǣȀȀǤȀ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
www.nature.com/scientificreports/
PRKN          Ǧ
ties. Others have previously reported fewer surviving neurons at the end of diferentiation towards a DA 
enriched population from iPSC’s derived from PRKN mutant parental patient  ibroblasts14. We investigated this 
during the diferentiation from iNPC’s to DA neurons. here was signiicant cell death occurring throughout dif-
ferentiation speciically in the PRKN mutant patient derived DA neurons; the percentage of cells surviving until 
the end of the diferentiation was signiicantly reduced (mean ± SD, controls 83.62 ± 4.8; parkin mutants 52.72 ± 
11.98); however, the same % yield of surviving neurons expressed DA markers between controls and PRKN 
mutants. We quantiied cell death using activated caspase 3 staining. he number of activated caspase 3 positive 
spots was higher in PRKN mutant neurons compared to controls at day 17, with a subsequent dramatic increase 
during the inal stage of diferentiation (% cells with activated caspase 3 staining at day 17 15% and at day 27 
64%); whereas in control neurons the level remains constant at approximately 7.8% (Fig. 2A). Furthermore, DA 
Figure 1.  Control and PRKN mutant iNPC derived dopaminergic iNeuron characterization throughout 
diferentiation. (A) Bright ield images (scale bar = 100 µm) at day 15 and day 27. he insets show magniied 
regions highlighting the processes of the neurons. (B–F) (i) Quantiication of each neuronal marker throughout 
diferentiation in controls (black bars) and PRKN mutants (grey bars) and (ii) shows representative images of a 
control and PRKN mutant at day 27. (Bii) Green is βIII tubulin and blue nucleus. (Cii) Red is MAP2 and blue 
the nucleus. (Dii) Red is NeuN and blue nucleus. (Eii) red is tyrsosine hydroxylase and blue the nucleus. (Fii) 
green is DAT and blue the nucleus. (G) he quantiication of mRNA expression levels for tyrosine hydroxylase 
in iNPC’s and day 27 neurons, showing a four fold increase in expression (black bars controls and grey bars 
PRKN mutants). (Hi) he quantiication at day 27 of Neurosensor staining which stains dopamine and 
noradrenaline showing 90% of cells staining positive in both controls (black bars) and PRKN mutants (grey 
bars). (ii) shows representative images of control and PRKN mutant at day 27. (I) he dopamine content and 
release assay in control and PRKN patient neurons. Intracellular and extracellular dopamine content assessed 
in neurons from three rounds of diferentiation for each condition. Neurons are either untreated, stimulated 
with potassium chloride or potassium chloride without magnesium in the bufer. Extracellular dopamine levels 
increase when neurons are stimulated with potassium chloride in both control (****p < 0.001) and PRKN mutant 
patient neurons (**p = 0.0032). J shows neuronal membrane potential in control (black line) and PRKN mutants 
(grey line) recorded at baseline and ater stimulation at time 200 s. All quantiication was done on at least three 
diferent diferentiations of four control and four PRKN mutant neurons; two way ANOVA with Tukey multiple 
comparisons correction was used.
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neurons from PRKN mutants displayed altered neuronal morphology at end stage diferentiation; being more 
round and less elongated (Fig. 2B,C; controls 1.92 ± 0.02; PRKN mutants 2.74 ± 0.2; p < 0.05 for cell roundness 
and controls 0.013 ± 0.0002; PRKN mutants 0.008 ± 0.001; p < 0.05 for cell elongation).
ơǢǦ
tional abnormalities in PRKNǤ Recent work has shown direct reprogramming 
methods retain the age characteristics of the donor ibroblasts; importantly this also includes the switch to 
oxidative phosphorylation during direct reprogramming and reductions in mitochondrial function and gene 
expression in the neurons generated from aged donors rather than those generated from younger  donors23. We 
therefore sought to understand the metabolism in our system, which utilises direct conversion of ibroblasts to 
iNPC’s rather than reprogramming to iPSC’s. In order to measure the percentage of ATP produced via glycolysis 
or oxidative phosphorylation in the cells throughout diferentiation; we measured the ATP content of the cells 
Figure 2.  Neuronal morphology and metabolic status during diferentiation. (A) Quantiication of activated 
caspase 3 in controls (black bars) and PRKN mutants (grey bars) throughout diferentiation. Signiicant increase 
in activated caspase 3 positive cells in PRKN mutants at day 22 (***p = 0.0008) and at day 27 (*p = 0.036). (B) A 
measure of cellular elongation; the PRKN mutant patient neurons have reduced cellular elongation compared 
to controls (*p = 0.029). (C) A measure of the roundness of the cells. he PRKN mutant patient neurons are 
more round than control neurons (*p = 0.029). (D,E) ATP production dependent on glycolysis or oxidative 
phosphorylation throughout diferentiation in control neurons (D shows control neurons absolute values 
and E shows the % of ATP produced when oxidative phosphorylation or glycolysis is inhibited as compared 
to untreated set to 100% in control neurons). ATP levels increase throughout diferentiation for both control 
and PRKN mutant neurons (data for PRKN mutant neurons shown in (F) and (G) in the same format as for 
control neurons, percentages have been calculated based upon PRKN mutant iNPC’s to calculate % ATP 
produced via OXPHOS or glycolysis). Control iNPC’s rely on glycolysis for ATP generation; this switches 
throughout diferentiation until at day 27 neurons are ~ 77% dependent on oxidative phosphorylation for ATP 
production (iNPC total ATP vs day 27 total ATP p = 0.0001; iNPC 2DG ATP vs day 27 2DG ATP p = 0.0001; 
day 27 oligomycin ATP vs day 27 2DG ATP p = 0.005). his switch occurs in PRKN mutant neurons also (F,G, 
iNPC ATP vs day 27 ATP p = 0.003; iNPC 2DG ATP vs day 27 2DG ATP p = 0.0001; day 27 2DG ATP vs day 27 
oligomycin ATP p = 0.0001. All experiments were repeated on three separate rounds of diferentiation in each 
control and PRKN mutant patient line (four diferent controls and PRKN mutant patient lines are included). Bar 
graphs represent mean with SD. All statistics done by two-way ANOVA test using Sidaks multiple comparisons 
test.
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ater treatment with various inhibitors. We treated with either oligomycin, to inhibit oxidative phosphorylation 
(speciically complex V), 2-Deoxyglucose to inhibit glycolysis (speciically hexokinase), both inhibitors together 
or vehicle only. his allowed us to understand the contribution of each metabolic pathway to generating ATP in 
the cells as iNPC’s and throughout diferentiation. he iNPC’s are reliant on glycolysis, as we can see from inhibi-
tion with 2-Deoxyglucose (glycolysis) inhibiting 70.4% of ATP produced; whereas oligomycin (oxidative phos-
phorylation) inhibits 3.4% of ATP levels (Fig. 2D; untreated 3.1 ± 0.6; OXPHOS inhibited 2.9 ± 0.7; glycolysis 
inhibited 0.9 ± 0.3 and Fig. 2E). he data shown in Fig. 2E are % calculations based on the ATP values in Fig. 2D. 
We have used the untreated value as 100%, and calculated how much ATP is still measurable ater inhibition 
of either OXPHOS (with oligomycin) or glycolysis (with 2-Deoxy-glucose) or both inhibitors. However during 
neuronal diferentiation the cells undergo a metabolic switch from glycolysis to oxidative phosphorylation; such 
that by the end stage of diferentiation neurons are reliant on oxidative phosphorylation for 77% of their energy 
generation (Fig. 2D, untreated 15.1 ± 1.4; OXPHOS inhibited 3.5 ± 1.2; glycolysis inhibited 8.5 ± 2.5 and Fig. 2E). 
his switch occurs in both control and PRKN mutant DA neurons (PRKN mutant data shown in Fig. 2F,G, cal-
culated in the same way as described above for control cells). At day 27 of diferentiation PRKN mutant neurons 
are reliant on OXPHOS for 80.8% of their ATP generation (Fig. 2G). It is interesting to observe the time point at 
which the dramatic increase in activated caspase 3 and cell death occurs in the PRKN mutant neurons (day 22) 
correlates with the metabolic switch towards OXPHOS reliance.
In order to fully understand mitochondrial function and morphology as this metabolic switch occurs and 
the role of parkin in this; we investigated mitochondrial function, morphology and mitophagy throughout dif-
ferentiation in control and PRKN mutant neurons. Previous reports have shown mitochondrial fragmentation 
in PRKN mutant iPSC derived  neurons29,30. We observe the same mitochondrial fragmentation at the end stage 
of diferentiation accompanied by an increase in mitochondrial number (Fig. 3A mitochondrial interconnectiv-
ity: controls 0.07 ± 0.003; PRKN mutants 0.04 ± 0.005 p < 0.05; Fig. 3B mitochondrial number (% normalised to 
controls): controls 100 ± 3.4; PRKN mutants 204 ± 35; p < 0.0001). In both control and PRKN mutant DA neurons 
throughout diferentiation mitochondria become more interconnected as the metabolic switch occurs. he 
Figure 3.  Mitochondrial morphology and function in dopaminergic iNeurons throughout diferentiation. 
(A) Mitochondria in both control (black bars) and PRKN mutant patient neurons (grey bars) elongate as the 
metabolic switch from glycolysis to oxidative phosphorylation begins at day 17 of diferentiation. By day 27 of 
diferentiation mitochondria in PRKN mutant patient neurons are fragmented compared to control neurons 
(***p = 0.0004). (B) Mitochondrial number is increased in PRKN mutant neurons (grey bars) compared to 
controls (black bars); (at day 12 **p = 0.008 and day 27 ****p < 0.0001). (C) Mitochondrial ROS production is 
signiicantly increased at day 27 of diferentiation in PRKN mutant neurons (grey bars) compared to controls 
(black bars; *p  = 0.037). (D) Mitochondrial membrane potential is decreased in PRKN mutant patient neurons 
(grey bars) throughout diferentiation, however the most dramatic and only signiicant reduction is at day 27 of 
diferentiation (**p = 0.003). E shows cellular ATP levels are reduced in PRKN mutant patient neurons at day 17 
(**p = 0.005) and day 27 (*p = 0.01) of diferentiation. All experiments were repeated on three separate rounds of 
diferentiation in each control and PRKN mutant patient line (four diferent controls and PRKN mutant patient 
lines are included). Bar graphs represent mean with SD. All statistics done by two-way ANOVA test using Sidaks 
multiple comparisons test.
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controls then return to a ‘normal’ morphology once this has happened (Fig. 3A). he increase in mitochondrial 
number in PRKN mutant DA neurons does not seem to be driven by increased biogenesis but rather the total 
mitochondrial content remains fairly constant however mitochondria are smaller and more fragmented in the 
PRKN mutant DA neurons. here is much debate in the literature as to whether the energy defect or increased 
ROS production is more detrimental in PD. We found dramatically increased mitochondrial ROS levels at end 
stage of diferentiation (controls 0.17 ± 0.018; PRKN mutants 0.6 ± 0.15; *p < 0.05; Fig. 3C). here is no change 
in mitochondrial ROS levels at earlier stages of diferentiation. In terms of mitochondrial function, we show 
that mitochondrial membrane potential is signiicantly reduced only at end stage diferentiation (MMP controls 
0.02 ± 0.004, PRKN mutant 0.003 ± 0.002, ****p < 0.001; Fig. 3D). However, there is a worsening trend in MMP 
decreases as diferentiation continues. A similar pattern is observed for cellular ATP levels with increasing dei-
cits as diferentiation progresses. he irst signiicant decrease in ATP levels is observed when the neurons are 
becoming reliant on oxidative phosphorylation at day 17 of diferentiation (controls 100 ± 5.5, parkin mutants 
82 ± 4.3, *p < 0.05; Fig. 3E). At the end stage of diferentiation the deicit is more severe (% normalised to controls: 
controls 100 ± 15, PRKN mutant 61 ± 15; ****p < 0.01; Fig. 3E). Taking the above data together we see dramatic 
changes in mitochondrial function and morphology, which are only revealed in PRKN mutant neurons as the 
metabolic switch occurs from glycolysis to oxidative phosphorylation; accompanied by a dramatic increase in 
mitochondrial ROS levels once this switch has taken place.
Mitophagy rates are higher in PRKN mutant neurons with glycolytic capacity before becomǦ
ing defective when neurons undergo a metabolic switch. As parkin is known to function in a well 
characterised parkin dependent mitophagy pathway targeting dysfunctional or damaged mitochondria for deg-
radation; we developed a live imaging assay to assess both basal and induced mitophagy rates in the neurons 
throughout diferentiation. his assay relies upon live staining of the total mitochondrial population and the 
lysosomal population combined with advanced high content imaging acquisition, data processing and analy-
sis. At 12 days diferentiation, when cells are positive for the pan neuronal marker βIII tubulin but are not yet 
DA and are glycolytic, PRKN mutant neurons have very similar rates of basal mitophagy as controls (controls 
0.08 ± 0.4; PRKN mutants 0.09 ± 0.6, Fig. 4Ai). When mitophagy is induced using treatment with mitochondrial 
inhibitors antimycin A and oligomycin, in these neurons the PRKN mutant neurons mount a higher response to 
global mitochondrial inhibition but they cannot sustain mitophagy for as long as the control neurons are able to 
(Fig. 4Aii). However, at day 17 of diferentiation when neurons are approximately 50/50 reliant on glycolysis and 
oxidative phosphorylation PRKN mutant neurons have higher basal mitophagy levels than controls (controls 
0.07 ± 0.03, PRKN mutants 0.09 ± 0.05, Fig. 4Bi) and again mount a higher response to mitophagy induction 
with mitochondrial inhibitor treatment but cannot sustain that level of mitophagy overtime (Fig. 4Bii). Finally, 
at the end stage of diferentiation when neurons are reliant on oxidative phosphorylation PRKN mutant neurons 
have a severe deicit in basal and induced mitophagy with mitochondrial inhibitors (Fig. 4C basal mitophagy 
controls 0.09 ± 0.025, PRKN mutants 0.025 ± 0.008; induced mitophagy controls 0.3 ± 0.09, PRKN mutants 0.1 ± 
0.01, p < 0.01). Representative images of the live mitophagy assay are shown in Supplementary Fig. 1. We used 
two alternative methods of evaluating mitophagy rates previously validated 31,32; using these methods we found 
very similar results throughout diferentiation and at endpoint (Fig. 4D, E). Tomm20 amount is increased in 
PRKN mutant patient derived neurons, indicating less mitophagy aligning with the mitophagy rates measured 
using the live and ixed assays. Of note, these results show that DA iNeurons with diferent PRKN mutations have 
varying magnitude of Tomm20 build up. PRKN A has a compound heterozygote change with a point mutation 
and exon 3 deletion, whereas PRKN B also has a compound heterozygote change with exon 4–7 deletion and 
c203_204 deletion AG. Varying efects of PRKN mutations on mitophagy has been observed before in cell lines 
expressing various  mutations33,34 and our data suggest it is also observable in patient derived cells.
Figure 4.  Mitophagy throughout dopaminergic iNeuron diferentiation. (A–C) Quantiication of percentage 
of mitochondria undergoing basal (i) or induced with mitochondrial inhibitors antimycin A and oligomycin 
(ii) mitophagy per cell over time at day 12 (A), day 17 (B) or day 27 of diferentiation (C). Graphs represent 
the quantiication of mitochondria undergoing mitophagy over time. Basal mitophagy is unaltered in PRKN 
mutants (grey lines) compared to controls (black lines) at day 12 of diferentiation (Ai); however by day 17 basal 
mitophagy is increased in PRKN mutants (p = 0.019, tested using ANOVA repeated measures across all time 
points; Bi) and at endpoint of diferentiation day 27, PRKN mutants have signiicantly reduced basal mitophagy 
levels (p = 0.011, tested using ANOVA repeated measures across all time points; Ci). Induced mitophagy 
(induced with mitochondrial inhibitor treatment) is increased in PRKN mutants initially ater induction at day 
12 (*p < 0.05, Sidaks post-test; Aii); the same pattern is seen at day 17, although without statistical signiicance 
(Bii) however by day 27 induced mitophagy is signiicantly lower in PRKN mutant neurons (*p  = 0.0113, 
tested using ANOVA repeated measures across all time points; Cii). (D) Quantiication of mitophagy using 
an alternative measure; showing the same pattern as the live assay. No diference at day 12, an increase at day 
17 in the PRKN mutants (grey bars) compared to controls (black bars, **p = 0.0016) and a reduction at day 27 
(**p = 0.0035). All experiments were repeated on three separate rounds of diferentiation in each control and 
PRKN mutant patient line (four diferent controls and PRKN mutant patient lines are included). Bar graphs 
represent mean with SD. (E) Quantiication of the amount of Tomm20. PRKN mutant neurons have increased 
Tomm20 amounts at day 27 of diferentiation as compared to control A (PRKN A *p = 0.04, PRKN B *p = 0.02). 
n = 3 for each line.
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    ? ? ?   ? ? ?    Ƥ 
PRKNǤ In order to evaluate if the driving mechanism in PRKN mutant DA neurons is 
the loss of energy production by the mitochondria or the dramatically increased mitochondrial ROS production, 
we treated the end stage day 27 neurons with the known potent intracellular redox-modulating agents KH176 
and  KH176m35 currently in clinical trials in mitochondrial patients with m.3243A>G spectrum  disorders36. 
KH176 and its quinone metabolite KH176m were identiied from a screen in ibroblasts from patients with 
primary mitochondrial diseases. he mechanism of action is known to be interaction with the thioredoxin sys-
tem and speciically the peroxiredoxin machinery, and are able to rescue both in vitro and in vivo models of 
primary complex I  deiciency35. In addition, we have previously showed that KH176 is actively metabolised to 
 KH176m35. In agreement with the mechanism of action treatment with KH176 and KH176m decreased mito-
chondrial ROS production to control levels ater 24 h treatment (Fig. 5A, control A vehicle treated 0.16 ± 0.006; 
control A KH176 treated 1 µM 0.14 ± 0.02; PRKN mutant A vehicle treated 0.7 ± 0.15; PRKN mutant A KH176 
treated 1 µM 0.12 ± 0.05; p < 0.001). KH176 and KH176m treatment had no signiicant efects on mitochondrial 
function (MMP or cellular ATP levels) or mitochondrial morphology parameters (Fig. 5B–D). Treatment with 
KH176 and KH176m did show a mild efect on neuronal morphology ater only 24 h of treatment; with the 
resulting neurons being less round ater treatment; a morphology closer to control neurons (Fig. 5E, cell round-
ness: control A vehicle treated 1.5 ± 0.09; control A KH176 treated 1 µM 1.6 ± 0.06; PRKN mutant A vehicle 
treated 3.1 ± 0.6; PRKN mutant A KH176 treated 1 µM 2.2 ± 0.6). KH176 or KH176m have not been assessed 
Figure 5.  Treatment of dopaminergic iNeurons with KH176 and KH176m. (A) Mitochondrial ROS levels are 
signiicantly reduced with treatment of both KH176 and KH176m (n = 3 for each line presented, 2 way ANOVA 
with Sidaks multiple comparisons test ***p < 0.0001). (B) Mitochondrial membrane potential is signiicantly 
reduced in PRKN mutant patient neurons however treatment with KH176 and KH176m has no efect on 
mitochondrial membrane potential (2 way ANOVA with Sidaks multiple comparisons test **p = 0.0009 and 
0.025 respectively). (C) Cellular ATP levels are reduced in PRKN mutant neurons however treatment with 
KH176 and KH176m has no signiicant efect. (D) Mitochondria are more round in PRKN mutant patient 
neurons compared to controls, again treatment with KH176 and KH176m has no efect (2 way ANOVA with 
Sidaks multiple comparisons test **p = 0.0048 and ****p = 0.0001 respectively). (E) shows cellular roundness 
is increased in PRKN mutant neurons; treatment with KH176m at 100 nM has a signiicant efect of reducing 
neuronal roundness, indicating the neurons are more elongated and similar in morphology to the controls (2 
way ANOVA with Sidaks multiple comparisons test *p = 0.018 and **p = 0.0045 respectively). For (A)–(E) the 
black dotted line shows mean vehicle treated for controls and grey dotted line mean vehicle treated for PRKN, 
n = 3 for each line. Two way ANOVA with Sidaks multiple comparisons test used. (F) Basal mitophagy is 
reduced in PRKN mutant A (grey triangles) compared to control A (black triangles); treatment with KH176m 
at both 100 nM (squares) and 1000 nM (circles) concentrations increase basal mitophagy rates in both control 
A and PRKN mutant A (n = 2 for each line presented, 2 way ANOVA with Sidaks multiple comparisons test. 
P values described are for efect across multiple time points from 2 way ANOVA, control vehicle vs control 
KH176m 1000 nM p = 0.0088; control vehicle vs PRKN vehicle p = 0.0003; PRKN mutant A vehicle vs PRKN 
mutant A KH176m 100 nM p = 0.0001).
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before for an efect on mitophagy rates and it is unclear the efect, if any, of a redox restoring metabolite would 
have on the mitophagy pathway. We investigated if KH176m treatment could afect basal mitophagy rates in 
neurons from PRKN mutant A. We chose KH176m for these experiments as it has shown the most efect in 
the other assays outside of mitochondrial ROS; therefore we wanted to investigate if there was any additional 
mitochondrial and cellular beneit with KH176m treatment which was modulated via mitophagy; in addition 
as mentioned above KH176 is metabolised to KH176m in cells. Our data show a signiicant increase in basal 
mitophagy rates ater treatment with KH176m in both control and PRKN neurons (Fig. 5F, control A vehicle 
treated 1.14 ± 0.11, control A KH176m 100 nM 1.27 ± 0.11, control A KH176m 1000 nM 1.56 ± 0.15 PRKN 
mutant A vehicle treated 0.6 ± 0.05, PRKN mutant A KH176m 100 nM 0.9 ± 0.05, PRKN mutant A KH176m 
1000 nM 0.8 ± 0.08).

Our study is the irst to report successful reprogramming via the iNPC route of PD PRKN mutant patient ibro-
blasts; varying reprogramming methods depend on competent energy generation for successful  reprogramming23. 
We have previously reported severe mitochondrial abnormalities in PRKN mutant  ibroblasts5; reprogramming of 
ibroblasts with a reduction in metabolic function can be challenging using iPSC  routes23 however here we show 
metabolically challenged ibroblasts can be reprogrammed using this direct reprogramming route. Recently oth-
ers have used alternative direct reprogramming methods to generate dopamine like neuronal cells from sporadic 
and LRRK2 Parkinson’s patient  cells37–39. hese studies showed several alternative reprogramming routes can 
lead to viable dopaminergic neuronal like cells; with each group assessing the dopaminergic qualities of the cells 
produced. Furthermore we have recently reported use of this reprogramming route to generate dopaminergic 
neurons from sporadic PD ibroblasts; in that study we found the mitochondrial abnormalities exasperated in the 
neurons compared to the ibroblasts from the same  patient40. he speciic method we have used here, the iNPC 
derived route has proved a useful model to study familial and sporadic forms of neurodegenerative diseases thus 
far; astrocytes derived from Motor Neuron Disease (MND) patients display neuronal toxicity when in co-culture 
with WT neurons similar to that seen with primary astrocytes from post-mortem biopsies from MND patients. 
Furthermore both iAstrocytes and iNeurons were recently used to investigate mechanisms of cell toxicity in 
C9orf72 dependent Motor Neuron  Disease24–27,41,42. We report the generation of high yield of DA neurons from 
iNPC’s. he DA yield we achieved via this method is higher than reported via the iPSC diferentiation route and 
similar or higher than that found with alternative direct reprogramming routes. We also note, the processes of 
the neurons generated via iNPC reprogramming are shorter than those from iPSC derived neurons. We hypoth-
esize this is due to the retention of age characteristics during direct reprogramming methods; whereas iPSC 
derived neurons are more embryonic in nature and similar to primary cultures generated from mice. However, 
this requires further investigation to fully understand the mechanisms involved. We ind more cell death in the 
PRKN mutant DA neurons throughout diferentiation; less eicient diferentiation has been reported by others for 
PRKN mutant patient neurons via iPSC reprogramming  route13. It is interesting that less eicient diferentiation 
from PRKN mutant neurons has now been reported using both direct and indirect reprogramming methods; 
this would suggest this phenotype could be determined by genotype as opposed to reprogramming route. Our 
control and patient groups were aged matched, however ageing changes in the primary ibroblasts could also 
alter reprogramming and diferentiation properties of cells. his would be interesting to study in a larger cohort 
over a wide age range. We also report iNPC derived PRKN mutant DA neurons are smaller and less elongated 
than controls. he increased cell death has been suggested to be dependent on the mitochondrial status of the 
cell rather than  genotype43. Our data would support this however further work to systematically test this would 
be useful to assess correlation between genotype and metabolic status.
Our study investigating mitochondrial function and morphology throughout diferentiation suggests the 
increased cell death seen in PRKN mutant DA neurons coincides with the neurons undergoing a metabolic 
switch from glycolysis to oxidative phosphorylation. We show the iNPC derived neurons have a clear switch in 
metabolism at day 22 with dependence on oxidative phosphorylation rather than glycolysis with a concurrent 
increase in the total amount of ATP in the neurons. his allows us to study mitochondrial function in these 
neurons which are metabolically more aligned to adult neurons in vivo (which are oxidative phosphorylation 
dependent) rather than embryonic neurons (glycolysis dependent)44. Our data show that, while this metabolic 
switch is occurring, mitochondrial morphology changes; as the neurons become more oxidative phosphorylation 
dependent the mitochondria become more interconnected in both controls and PRKN mutants; we suggest this 
a change in mitochondrial morphology to allow the neurons to become reliant on oxidative phosphorylation. 
Once the metabolic switch has occurred mitochondrial morphology can return to the normal shape; however 
PRKN mutant neurons once OXPHOS dependent have increased mitochondrial fragmentation. his is opposite 
to the mitochondrial morphology phenotype we have previously reported in PRKN mutant  ibroblasts5; however 
others in the literature have previously reported a more fragmented mitochondrial network associated with PRKN 
 deiciency45; this is likely to be a cell type speciic efect; our data suggesting this is dependent on the metabolic 
status of the cells. As outlined in the introduction, several studies have found mitochondrial abnormalities in 
PRKN mutant patient derived neurons derived via iPSC reprogramming  route10–17. Here we show some of the 
same abnormalities are present in PRKN mutant generated via a direct reprogramming route; in addition we have 
shown how this mitochondrial phenotype develops throughout diferentiation and built upon previous studies 
in patient derived neurons to investigate multiple parameters related to neuronal health and mitochondria in 
the same population of neurons.
Previous studies utilising iPSC derived PRKN mutant neurons have found mitochondrial abnormalities 
including defective mitophagy when induced using  CCCP12; however recent in vivo data from mouse and Dros-
ophila models have shown little reduction in mitophagy on a PRKN or PINK1 deicient  background20. Here we 
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show basal and induced mitophagy levels in PRKN mutant patient derived DA neurons; furthermore we ind 
in a PRKN mutant background mitophagy levels are dependent on cellular energetic status. In cells which are 
dependent on glycolysis for energy production, basal and induced mitophagy are increased (or at least the same 
as controls) in PRKN mutant patient cells however upon the switch to OXPHOS dependency the PRKN mutant 
DA neurons have impaired basal mitophagy and are unable to mount a response to global mitochondrial dysfunc-
tion. Our data support the inding in PRKN deicient Drosophila that adult neurons increase levels of mitophagy 
during ageing however PRKN deicient neurons  cannot22. he speciic mitophagy pathway being utilised in these 
PRKN mutant neurons is not clear and requires further investigation.
Although mitochondrial abnormalities have been clearly identiied by many in PD models; there is debate 
as to whether the detrimental component of this is actually loss of energy or increased ROS production. Here 
we show that mitochondrial ROS levels are signiicantly increased only at end stage of diferentiation when the 
neurons are OXPHOS dependent and have severe mitochondrial abnormalities. he increase in mitochondrial 
ROS is striking in all four PRKN mutant patient neuron lines. Previous studies have shown an increase in ROS 
in some PRKN mutant patient neurons but not in others and have measured total cellular ROS rather than mito-
chondrial speciic ROS which could explain why the data we present here is more consistent across the group of 
patients. Targeting mitochondrial dysfunction for a potential therapeutic to slow or stop disease progression is 
an attractive option with many mitochondrial targeted therapeutics shown to be efective in various models of 
PD (recently  reviewed2,46). Diferent therapeutic strategies are being developed; some primarily acting to boost 
energy deicits whilst others are targeting ROS production. Here we show that treatment with the known redox-
modulating compounds KH176 and KH176m dramatically reduces the mitochondrial ROS production with no 
signiicant efect on MMP or cellular ATP levels; however, KH176 and KH176m do have a mild beneicial efect 
on the neuronal morphology of the PRKN mutant neurons. hese efects could be modulated by an increase in 
basal mitophagy ater treatment with KH176m. he increase in basal mitophagy is perhaps counter intuitive with 
a compound which reduces mitochondrial ROS production; however we hypothesise the mitophagy efects are 
due to a restoring of the redox balance in the cell, enabling some of the damaged mitochondria which have built 
up to be recycled. his mechanism requires further investigation in this and other models. Our data suggest a 
reversal of the energy deicit may not be required to have beneicial neuronal efects; however further work needs 
to be done to fully investigate this, particularly over a longer term treatment.
In conclusion, our study utilises the iNPC technology to generate a high DA population of neurons which 
both express markers of DA neurons and release dopamine upon induction. Our data shows a predominant mito-
chondrial dysfunction present in these neurons which is far more pronounced than that found in the primary 
patient  ibroblasts5. Our study builds on previous work as for the irst time neuronal properties, mitochondrial 
functional, morphological and mitophagy parameters are assessed in the same neurons; neurons which express 
TH and contain dopamine. Finally, our study highlights mitophagy as an energetic dependent process, which, 
in a PRKN mutant background varies considerably if the cells are glycolytic or OXPHOS dependent. his under-
lines the need to study mitophagy processes with endogenous levels of proteins in cell types which are relevant 
for disease and understand the energetic proile of the cells in order to be able to relate the indings to disease 
mechanism. Further studies to undertake detailed biochemical assessments of neuronal metabolism in this model 
in addition to utilising this model to assess putative neuroprotective compounds are warranted.
Methods
   Ƥǡ     ǯǤ Primary ibroblasts were 
obtained from Coriell Cell Repository (coriell.org) controls: ND29510, GM09400, GM23967 and AG06882; 
PRKN mutant patients: ND30171, ND31618, ND40067 and ND40078 (details of mutation, age and sex are given 
in Table 1). Control and PRKN mutant groups were age and sex matched (controls 57 ± 6.8; parkin mutants 
53 ± 8 years). Fibroblasts were cultured in EMEM as previously  described5. iNPC’s were generated as previ-
ously  described47. iNPC’s were maintained in DMEM/Ham F12 (Invitrogen); N2, B27 supplements (Invitrogen) 
and FGFb (Peprotech) in ibronectin (Millipore) coated tissue culture dishes and routinely sub-cultured every 
2–3 days using accutase (Sigma) to detach them.
Table 1.  Table giving details of the control and PRKN mutant patient lines used in this study. Further 
information can be found at https ://corie ll.org and https ://stemc ells.ninds genet ics.org.
Reference Age M/F Mutation Line ID
ND30171 54 M ARG42PRO EX3DEL Parkin A
ND40067 44 F EX4-7DEL c203_204 DEL AG Parkin B
ND31618 63 F ARG42PRO Parkin C
ND40078 51 F ARG275TRP/ARG275GLN Parkin D
AG06882 64 M Control A
ND29510 55 F Control B
GM23967 52 M Control C
GM09400 F Control D
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ơǯǤ Neurons were diferentiated from iNPC’s as previously  described40. 
Briely, iNPCs are plated in a 6-well plate and cultured for 2 days in DMEM/F-12 medium with Glutamax sup-
plemented with 1% NEAA, 2% B27 (Gibco) and 2.5 µM of DAPT (Tocris). On day 3, DAPT is removed and 
the medium is supplemented with 1 µM smoothened agonist (SAG; Millipore) and FGF8 (75 ng/ml; Peprotech) 
for additional 10  days. Neurons are replated at this stage. Subsequently SAG and FGF8 are withdrawn and 
replaced with BDNF (30  ng/ml; Peprotech), GDNF (30  ng/ml; Peprotech), TGF-b3 (2  mM; Peprotech) and 
dcAMP (2 mM, Sigma) for 15 days.
ƪ ǡ  ƪ   Ǥ Neurons were plated and 
underwent immunocytochemistry staining as described  previously40. Cells are plated into 96 well plates and 
ixed using 4% paraformaldehyde for 30 min. Ater PBS washes cells are permeabilised using 0.1% Triton X-100 
for 10 min and blocked using 5% goat serum for 1 h. Cells are incubated with primary antibodies (Pax6 (Abcam); 
nestin (Abcam); GFAP (Abcam), tyrosine hydroxylase (Abcam); DAT (hermoFisher); β III tubulin (Millipore); 
Tomm20 (BD Biosciences); LC3 (MBL); activated caspase 3 (Cell Signalling); Map2 (Abcam); NeuN (Abcam)); 
at 4 degrees for 16 h. Cells are washed using PBS-Tween and incubated with Alexa Fluor conjugated secondary 
antibodies 488 and 568 (Invitrogen) and Hoescht (Sigma) 1 µM prior to imaging. Imaging was performed using 
the Opera Phenix high content imaging system (Perkin Elmer). Twenty ields of view were imaged per well; in 
seven z planes. Images were analysed using Harmony sotware; maximum projections were used for analysis.
Dopamine ELISA was performed as per the manufacturer’s instructions (Labor Diagnostika Nord GmbH&Co. 
KG). Dopamine release experiments, neurons were incubated in HBSS with  Ca2+ and  Mg2+ (Gibco by Life Tech-
nologies) for 30 min, or HBSS with  Ca2+ and  Mg2+ for 15 min and 56 mM KCl (Fisher chemical) for another 
15 min or HBSS without  Ca2+ and  Mg2+ (Gibco by Life Technologies) with 2 mM EDTA for 15 min and then 
56 mM KCL is added for another 15 min. Media is collected immediately; cells are harvested using accutase, 
centrifuged at 400g for 4 min and resuspended in 10 µl of PBS. EDTA 1 mM and Sodium Metabisulite (Sigma) 
4 mM are added to both the media and pellet to preserve the dopamine. he ELISA was read on a PheraStar plate 
reader (BMG Labtech) as per the manufacturer’s instructions; using the provided standard curve to calculate 
dopamine concentrations.
Neurons were incubated with 0.1 µM Neurosensor 521 (Sigma) and 1 µM Hoechst in media for 30 min 
at 37 degrees. Cells were washed in phenol red free media and imaged using InCell 2000 (GE Healthcare) 
using 60 × objective and 488 nm excitation for Neurosensor 521 and 405 nm excitation for Hoechst (method 
modiied  from48). Fiteen ields of view per well were imaged and at 3 wells per line on at least three rounds of 
diferentiation.
Neuronal membrane potential was measured using Fluovolt Membrane Potential Kit (hermoFisher) as 
per the manufacturer’s instructions. Experiments were performed under basal or depolarizing conditions ater 
treatment with isotonic potassium chloride solution (140 mM KCl, 5 mM NaCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 
20 mM HEPES, 20 mM Glucose, pH 7.4).
Mitochondrial function, morphology and mitophagy measurements. Neurons were plated in 96 
well plates; for MMP and morphology live imaging cells are incubated for 1 h at 37° with 50 nM tetramethyl-
rhodamine (TMRM), 1 µM rhodamine 123 and 1 µM Hoescht (Sigma), ater removal of dyes and replacement 
with phenol red free media plates are imaged using the Opera Phenix. Fiteen ields of view are imaged per well, 
in seven z planes. Images are analysed using Harmony sotware (Perkin Elmer). Segmentation protocols were 
established to segment the nuclei, mitochondria, and image region containing cytoplasm including projections. 
Analysis of number, size, intensity and morphology of mitochondria were calculated per image region using 
Harmony sotware (Perkin Elmer) using similar methodology as previously  established31. Cellular ATP meas-
urements are undertaken using ATPLite kit (Perkin Elmer) as per manufacturer’s instructions. To assess depend-
ency on OXPHOS or glycolysis, cells were pre-treated with oligomycin (Sigma) 10 µM to inhibit OXPHOS, or 
2-Deoxy Glucose (Sigma) 50 mM to inhibit glycolysis, or both inhibitors simultaneously, for 30 min at 37° and 
then ATP measurements were  performed49. From this we can calculated the % ATP levels setting untreated at 
each time point to 100%. Mitochondrial reactive oxygen species generation was assessed using mitochondrial 
NpFR2  probe50 incubated with cells at 20 µM and 1 µM Hoechst for 30 min at 37 °C, probes were removed and 
phenol red free media replaced. Cells were imaged using the Opera Phenix (Perkin Elmer). In order to assess 
mitophagy in live cells, cells were incubated for 1 h at 37 °C with 1 µM tetramethylrhodamine (TMRM), 1 µM 
Lysotracker Green (Invitrogen) and 1 µM Hoescht , before washing to remove luorescent probes. For the meas-
urement of induced mitophagy 2 µM Antimycin A (Sigma) and 5 µM oligomycin (Sigma) were added prior to 
imaging. Images were captured in time lapse every 18 min in the same ields of view, minimum 6 ields of view 
per well. Images generated from the live imaging experiments were analysed using Harmony (Perkin Elmer 
sotware). We developed protocols in order to segment nucleus, image region containing cytoplasm, mitochon-
dria, lysosomes, autolysosomes containing mitochondria. Maximal projection images were used for analysis. 
Mitochondria contained within lysosomes segmentation was set up in such a way to identify a mitophagy event 
when the overlap between mitochondria and lysosome was 100%.
Staining of cells using LC3 and Tomm20 (as described above) and subsequent imaging using Opera Phenix 
and image analysis was used to validate the live imaging mitophagy assay. he image segmentation and analysis 
was set up in Harmony sotware as previously  published31. Furthermore as an additional mitophagy read out we 
utilised the loss of Tomm20 signal from cells as previously  determined32.
Statistical tests. All experiments were performed on at least triplicate diferentiations for each control and 
PRKN mutant neuron or iNPC unless otherwise stated. Data are presented as mean ± standard deviation. Stu-
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dents t test was used when comparing between control and PRKN mutant patients. When comparing diferent 
timepoints throughout diferentiation a matched two way ANOVA was used with multiple comparisons using 
Sidaks or Tukey correction. Treatment data was analysed using two way ANOVA and multiple comparisons. All 
statistical tests were carried out using GraphPad Prism sotware.
Received: 2 March 2020; Accepted: 19 August 2020
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